In vitro activity of the αvβ3 integrin antagonist RGDechi-hCit on malignant melanoma cells

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 871-880

  Pisano, Marina ^a   De Paola, Ivan ^a   Nieddu, Valentina ^a   Sassu, Ilaria ^a   Cossu, Sara ^a   Galleri, Grazia ^b   Del Gatto, Annarita ^a   Budroni, Mario ^c   Cossu, Antonio ^d   Saviano, Michele ^a   Palmieri, Giuseppe ^a   Zaccaro, Laura ^a   Rozzo, Carla ^a  

^a CNR   (Italy)

^b Porto Conte Ricerche Srl   (Italy)

^c Local Health Unit 1   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cell adhesion; Cell migration; Integrin v 3; Malignant melanoma; RGD peptide

Indexed keywords

ANTINEOPLASTIC AGENT; RGDECHI HCIT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CYTOFLUOROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA; PEPTIDES;

EID: 84875902878     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. MacKie RM, Hauschild A and Eggermont AM: Epidemiology of invasive cutaneous melanoma. Ann Oncol 20(Suppl 6): vi1- vi7, 2009.
2. Berwick M, Erdei E and Hay J: Melanoma epidemiology and public health. Dermatol Clin 27: 205-214, 2009.
3. Bhatia S, Tykodi SS and Thompson JA: Treatment of metastatic melanoma: An overview. Oncology 23: 488-496, 2009.
4. Desgrosellier JS and Cheresh DA: Integrins in cancer: Biological implications and therapeutic opportunities. Nature Rev Cancer 10: 9-22, 2010.
5. Avraamides CJ, Garmy-Susini B and Varner J: Integrins in angiogenesis and lymphangiogenesis. Nature Rev Cancer 8: 604-617, 2008.
6. Marshall JF, Rutherford DC, Happerfield L, Hanby A, McCartney AC, Newton-Bishop J and Hart IR: Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br J Cancer 77: 522-529, 1998.
7. McGary C, Chelouche Lev D and Bar-Eli M: Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 1(5): 459-465, 2002.
8. Kuphal S, Bauer R and Bosserhoff AK: Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2: 195-222, 2005.
9. Jin H and Varner J: Integrins: Roles in cancer development and as treatment targets. Br J cancer 90: 561-565, 2004.
10. Hood JD and Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100, 2002.
11. Mizejewski GJ: Role of integrins in cancer: Survey of expression patterns. Proc Soc Exp Biol Med 222: 124-138, 1999.
12. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL and Arnaout MA: Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 296: 151-155, 2002.
13. Marinelli L, Gottschalk KE, Meyer A, Novellino E and Kessler H: Human integrin αvβ5 homology modeling and ligand binding. J Med Chem 47: 4166-4177, 2004.
14. Cox D, Brennan M and Moran N: Integrins as therapeutic targets: Lessons and opportunities. Nat Rev Drug Discov 9(10): 804-820, 2010.
15. Tamkun JW, DeSimone DW, Fonda D, Patel RS, Buck C, Horwitz AF and Hynes RO: Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 46: 271-82, 1986.
16. Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, Wu Y, Gong Z, Li A, Xu S, Zhou J and Li G: JWA regulates melanoma metastasis by integrin αvβ3 signaling. Oncogene 29(8): 1227-1237, 2010.
17. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL and Kessler H: N-Methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists. J Med Chem 42(16): 3033-3040, 1999.
18. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB and Stupp R: Cilengitide: An RGD pentapeptide αvβ3 and αvβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 7(3): 339-354, 2011.
19. Tabatabai G, Weller M, Nabors B, Picard M, Reardon D, Mikkelsen T, Ruegg C and Stupp R: Targeting integrins in malignant glioma. Target Oncol 5: 175-181, 2010.
20. Perdih A and Dolenc MS: Small molecule antagonists of integrin receptors. Curr Med Chem 17(22): 2371-2392, 2010.
21. Del Gatto A, Zaccaro L, Grieco P, Novellino E, Zannetti A, Del Vecchio S, Iommelli F, Salvatore M, Pedone C and Saviano M: Novel and selective αvβ3 receptor peptide antagonist: Design, synthesis, and biological behavior. J Med Chem 49: 3416-3420, 2006.
22. Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone C and Salvatore M: Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with αvβ5. Clin Cancer Res 15: 5224-5233, 2009.
23. Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, Saviano M, Del Gatto A, Trimarco B, Pedone C, Zaccaro L and Iaccarino G: Evaluation of the antiangiogenic properties of the new selective αvβ3 integrin antagonist RGDechi-hCit. J Transl Med 9: 7, 2011.
24. Lu H, Murtagh J and Schwartz EL: The microtubule binding drug laulimalide inhibits vascular endothelial growth factorinduced human endothelial cell migration and is synergistic when combined with docetaxel (Taxotere). Mol Pharmacol 69: 1207-1215, 2006.
25. Astrof S and Hynes RO: Fibronectins in vascular morphogenesis. Angiogenesis 12: 165-175, 2009.
26. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I and Schuch G: Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 27: 86, 2008.
27. Sadatmousavi P, Soltani M, Nazarian R, Jafari M and Chen P: Self-assembling peptides: potential role in tumor targeting. Curr Pharm Biotechnol 12(8): 1089-1100, 2011.
28. Zaccaro L, Del Gatto A, Pedone C and Saviano M: Peptides for tumour therapy and diagnosis: Current status and future directions. Curr Med Chem 16: 780-795, 2009.
29. Palmieri G, Casula M, Sini MC, Ascierto PA and Cossu A: Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med 11: 1052-1068, 2007.
30. Kueng W, Silber E and Eppenberger U: Quantification of cells cultured on 96-well plates. Anal Biochem 182: 16-19, 1989.
31. Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, Dettori MA, Delogu G, Ponzoni M and Rozzo C: Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer 6: 8, 2007.